News from the European Atherosclerosis Society Congress 2015
New EAS Consensus Statement
Side-effect and consequent non-adherence limit statin efficacy in practice
Muscle symptoms often result in poor adherence or treatment discontinuation in statin treated patients. Consequently the efficacy of these valuable therapies is compromised and, as a result, cardiovascular mortality in these patients may be increased by nearly 50%.
Responding to this critically important clinical issue, a Consensus Panel of The European Atherosclerosis Society (EAS) has issued a statement addressing these key questions:
- How should these symptoms be diagnosed and assessed?
- What do we know about the pathophysiology of myopathy caused by statins?
- What are current strategies for managing these patients?
- How could new treatment options including PCSK9 inhibitors improve management?